Helping research human cognition with MindCrowd.

Alzheimer’s publication profiles MindCrowd

A website that specializes in Alzheimer's and caregiving for those with the disease featured MindCrowd in an article. A writer from took the MindCrowd test and spoke with Dr. Matt Huentelman about the aim of the project. Here…
Even those with healthy brains can contribute in the fight against Alzheimer's.

TGen’s social media study is finalist for international social-impact award

CLASSY Awards recognizes Alzheimer's disease investigation by TGen PHOENIX, Ariz. - March 5, 2014, an innovative social-media investigation of Alzheimer's disease by the Translational Genomics Research Institute (TGen), is…
Matt Huentelman founded MindCrowd to study how cognition and memory change as people age. The results so far have supported his hypothesis- Test performance decreases with age
, ,

Arizona Republic reports MindCrowd goal of 1 million participants

This article in the Arizona Republic explains Dr. Huentelman's vision for MindCrowd and how scientists are going to use the test results to help find a cure for Alzheimer's. Huentelman, a scientific researcher at Phoenix-based Translational…
Mother Nature Network story encourages public to take MindCrowd test

Mother Nature Network story encourages public to take MindCrowd test

Mother Nature Network ran a story encouraging the public to take the MindCrowd test to help find a cure for Alzheimer's. The story includes an interview with Dr. Matt Huentelman, the force behind MindCrowd. Mother Nature Network story encourages…
Into the mind of Matt Huentelman. Memories matter. Let's fight against Alzheimer's.

Into the Mind of… Matt Huentelman

The TGen researcher explains why he’s using crowd- sourcing to better understand Alzheimer’s disease. In this weekly opinion section of The Arizona Republic, MindCrowd creator Dr. Matt Huentelman explains the MindCrowd project,…
One million people. One cause: MindCrowd.

MindCrowd Featured in the Phoenix Business Journal

“Before we can discover new treatments for brain-related diseases such as Alzheimer’s and Parkinson’s, we need to understand the human genetic blueprint – DNA – that determines how the brain works in healthy individuals,” he said.…